CN114916233A - 泛癌症早筛预测方法 - Google Patents
泛癌症早筛预测方法 Download PDFInfo
- Publication number
- CN114916233A CN114916233A CN202180005828.4A CN202180005828A CN114916233A CN 114916233 A CN114916233 A CN 114916233A CN 202180005828 A CN202180005828 A CN 202180005828A CN 114916233 A CN114916233 A CN 114916233A
- Authority
- CN
- China
- Prior art keywords
- cancer
- early
- expression profile
- data
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 75
- 201000011510 cancer Diseases 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 54
- 238000012216 screening Methods 0.000 title claims abstract description 35
- 230000014509 gene expression Effects 0.000 claims abstract description 40
- 229920002477 rna polymer Polymers 0.000 claims abstract description 17
- 238000011528 liquid biopsy Methods 0.000 claims abstract description 15
- 108091070501 miRNA Proteins 0.000 claims description 18
- 108700011259 MicroRNAs Proteins 0.000 claims description 12
- 238000011529 RT qPCR Methods 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 238000002790 cross-validation Methods 0.000 claims description 10
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 238000010606 normalization Methods 0.000 claims description 8
- 239000000090 biomarker Substances 0.000 claims description 7
- 238000012937 correction Methods 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 238000013399 early diagnosis Methods 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000002493 microarray Methods 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 230000001351 cycling effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000012706 support-vector machine Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000002679 microRNA Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Data Mining & Analysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- Public Health (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Software Systems (AREA)
- Artificial Intelligence (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
Abstract
一种泛癌症早筛预测方法，包括以下步骤：建立癌症患者族群及健康族群的微型核糖核酸表现图谱数据库，并据此建立泛癌症早筛预测方法；接下来，将受检者的液态活检样品中的微型核糖核酸表现图谱通过泛癌症早筛预测方法进行分析，以判断受检者是否可能已罹患癌症。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122481P | 2020-12-08 | 2020-12-08 | |
| US63/122,481 | 2020-12-08 | ||
| PCT/CN2021/136562 WO2022121960A1 (zh) | 2020-12-08 | 2021-12-08 | 泛癌症早筛预测方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114916233A true CN114916233A (zh) | 2022-08-16 |
Family
ID=81848310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180005828.4A Pending CN114916233A (zh) | 2020-12-08 | 2021-12-08 | 泛癌症早筛预测方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220180973A1 (zh) |
| CN (1) | CN114916233A (zh) |
| TW (1) | TWI829042B (zh) |
| WO (1) | WO2022121960A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024174260A1 (zh) * | 2023-02-24 | 2024-08-29 | 信标生医股份有限公司 | 基于液态活检的癌症早期筛检方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11551043B2 (en) | 2018-02-28 | 2023-01-10 | Visiongate, Inc. | Morphometric detection of malignancy associated change |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103237901A (zh) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | 用于治疗诊断的生物标志物 |
| WO2017099414A1 (ko) * | 2015-12-07 | 2017-06-15 | 엘지전자 주식회사 | 암 진단용 마이크로rna 바이오마커 발굴 방법 및 그 이용 |
| CN111748633A (zh) * | 2020-08-04 | 2020-10-09 | 广东省第二人民医院（广东省卫生应急医院） | 一种特征miRNA表达谱组合及头颈鳞状细胞癌早期预测方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016089553A1 (en) * | 2014-12-03 | 2016-06-09 | Biodesix, Inc. | Early detection of hepatocellular carcinoma in high risk populations using maldi-tof mass spectrometry |
| CN108300784A (zh) * | 2018-02-05 | 2018-07-20 | 杭州更蓝生物科技有限公司 | 一种用于预测牙龈癌的miRNA组合物 |
| TWI758670B (zh) * | 2018-12-24 | 2022-03-21 | 奎克生技光電股份有限公司 | 健康風險評估方法 |
| CN111793692A (zh) * | 2020-08-04 | 2020-10-20 | 中国科学院昆明动物研究所 | 一种特征miRNA表达谱组合及肺鳞癌早期预测方法 |
-
2021
- 2021-12-08 TW TW110145861A patent/TWI829042B/zh active
- 2021-12-08 WO PCT/CN2021/136562 patent/WO2022121960A1/zh active Application Filing
- 2021-12-08 US US17/544,947 patent/US20220180973A1/en active Pending
- 2021-12-08 CN CN202180005828.4A patent/CN114916233A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103237901A (zh) * | 2010-03-01 | 2013-08-07 | 卡里斯生命科学卢森堡控股有限责任公司 | 用于治疗诊断的生物标志物 |
| WO2017099414A1 (ko) * | 2015-12-07 | 2017-06-15 | 엘지전자 주식회사 | 암 진단용 마이크로rna 바이오마커 발굴 방법 및 그 이용 |
| CN111748633A (zh) * | 2020-08-04 | 2020-10-09 | 广东省第二人民医院（广东省卫生应急医院） | 一种特征miRNA表达谱组合及头颈鳞状细胞癌早期预测方法 |
Non-Patent Citations (2)
| Title |
|---|
| NIKHIL CHEERLA等: "MicroRNA based Pan-Cancer Diagnosis and Treatment Recommendation", 《BMC BIOINFORMATICS》, vol. 18, no. 32, 13 January 2017 (2017-01-13), pages 1 - 11, XP021264798, DOI: 10.1186/s12859-016-1421-y * |
| 王义: "支持向量机在医学及生物方面的应用", 《硕士学位论文》, 3 September 2007 (2007-09-03), pages 1 - 38 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024174260A1 (zh) * | 2023-02-24 | 2024-08-29 | 信标生医股份有限公司 | 基于液态活检的癌症早期筛检方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI829042B (zh) | 2024-01-11 |
| US20220180973A1 (en) | 2022-06-09 |
| WO2022121960A1 (zh) | 2022-06-16 |
| TW202223103A (zh) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102369294B (zh) | 非小细胞肺癌标记物及其检测方法、试剂盒和生物芯片 | |
| CN101942502B (zh) | 胰腺癌标记物及其检测方法、试剂盒和生物芯片 | |
| CN107574243B (zh) | 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法 | |
| CN104903468B (zh) | 用于帕金森氏病的新诊断MiRNA标志物 | |
| EP3524689A1 (en) | Method for predicting the prognosis of breast cancer patient | |
| KR20170035932A (ko) | 위암 진단용 microrna 바이오마커 | |
| KR101672531B1 (ko) | 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도 | |
| CN104968802B (zh) | 作为诊断标志物的新miRNA | |
| CN101988059B (zh) | 胃癌检测标记物及其检测试剂盒和生物芯片 | |
| WO2020048518A1 (zh) | 一组用于髓母细胞瘤分子分型的基因及其应用 | |
| CN114916233A (zh) | 泛癌症早筛预测方法 | |
| CN106148538B (zh) | microRNA标志物组及其在制备评价乳腺癌化疗敏感性试剂盒中的应用 | |
| CN105518154B (zh) | 脑癌检测 | |
| CN106661623A (zh) | 使用miRNA生物标志物相对于多发性硬化诊断视神经脊髓炎 | |
| TWI758670B (zh) | 健康風險評估方法 | |
| CN111424085B (zh) | tRNA来源片段在制备乳腺癌诊断试剂中的应用 | |
| CN105779580A (zh) | 评估罹患结肠直肠癌风险的方法及标志物 | |
| WO2014171800A1 (ko) | 조기 유방암 예후 예측 진단용 자동화 시스템 | |
| CN107299129A (zh) | 循环核酸作为乳腺癌生物标志物的应用 | |
| CN115772524A (zh) | 一种标志物组合及其在制备诊断甲状腺癌的试剂中的应用 | |
| CN111808966B (zh) | miRNA在诊断乳腺癌患病风险的应用 | |
| WO2024174260A1 (zh) | 基于液态活检的癌症早期筛检方法 | |
| TWI854510B (zh) | 基於液態活檢的癌症早期篩檢方法 | |
| US20240287613A1 (en) | Cancer early detection method using liquid biopsy | |
| WO2024047914A1 (en) | Analysis method, kit, and detection device for cancer diagnosis by means of microrna expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40075724 Country of ref document: HK |